Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J PARKS

Showing results (341-350 of 557) with videos related to

Pageof 56
Sort By:
The American Journal of Clinical Nutrition|December 21, 2014
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesisJoseph J Lee, Jennifer E Lambert, Yelena Hovhannisyan, et al.
JAMA Network Open|February 18, 2025
Tobacco and E-Product Use by US Adults With DisabilitiesMichael J Parks, Daniela Marshall, Heather L Kimmel, et al.
JMIR Human Factors|November 3, 2023
Association Between Clinician-Level Factors and Patient Outcomes in Virtual and In-Person Outpatient Treatment for Substance Use Disorders: Multilevel AnalysisJustine W Welsh, Siara I Sitar, Michael J Parks, et al.
Molecular Carcinogenesis|September 6, 2019
p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancerChae Young Han, David A Patten, Seung Gee Lee, et al.
Biochemistry|August 22, 1995
Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell lineS G Blanchard, C O Harris, O R Ittoop, et al.
Biochemistry|November 18, 1998
Structural characterization and optimization of antibody-selected phage library mimotopes of an antigen associated with autoimmune recurrent thrombosisD S Sem, B L Baker, E J Victoria, et al.
Human Gene Therapy|January 5, 1999
High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicityN Morral, R J Parks, H Zhou, et al.
Preventive Medicine|October 22, 2019
Financial incentives and proactive calling for reducing barriers to tobacco treatment among socioeconomically disadvantaged women: A factorial randomized trialMichael J Parks, Kelly D Hughes, Paula A Keller, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2014
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonistsTerrence L Smalley, Sharon Boggs, Justin A Caravella, et al.
Human Gene Therapy|August 14, 1999
Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectorsL Pastore, N Morral, H Zhou, et al.
Pageof 56

Showing results (341-350 of 557) with videos related to

Sort By:
Pageof 56
The American Journal of Clinical Nutrition|December 21, 2014
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesisJoseph J Lee, Jennifer E Lambert, Yelena Hovhannisyan, et al.
JAMA Network Open|February 18, 2025
Tobacco and E-Product Use by US Adults With DisabilitiesMichael J Parks, Daniela Marshall, Heather L Kimmel, et al.
JMIR Human Factors|November 3, 2023
Association Between Clinician-Level Factors and Patient Outcomes in Virtual and In-Person Outpatient Treatment for Substance Use Disorders: Multilevel AnalysisJustine W Welsh, Siara I Sitar, Michael J Parks, et al.
Molecular Carcinogenesis|September 6, 2019
p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancerChae Young Han, David A Patten, Seung Gee Lee, et al.
Biochemistry|August 22, 1995
Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell lineS G Blanchard, C O Harris, O R Ittoop, et al.
Biochemistry|November 18, 1998
Structural characterization and optimization of antibody-selected phage library mimotopes of an antigen associated with autoimmune recurrent thrombosisD S Sem, B L Baker, E J Victoria, et al.
Human Gene Therapy|January 5, 1999
High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicityN Morral, R J Parks, H Zhou, et al.
Preventive Medicine|October 22, 2019
Financial incentives and proactive calling for reducing barriers to tobacco treatment among socioeconomically disadvantaged women: A factorial randomized trialMichael J Parks, Kelly D Hughes, Paula A Keller, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2014
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonistsTerrence L Smalley, Sharon Boggs, Justin A Caravella, et al.
Human Gene Therapy|August 14, 1999
Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectorsL Pastore, N Morral, H Zhou, et al.
Pageof 56